Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Replimune, Inc.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05733611CT.gov RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marinesco-Sjogren Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| rp3 (this asset) | Replimune, Inc. | P2 | CCC · 53 |
| Irinotecan | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Cetuximab | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Nivolumab | Pfizer | P2 | B |
| Ipilimumab | Pfizer | P2 | B |
| Binimetinib | Pfizer | P2 | B |
| Regorafenib | Sun Yat-sen University | P2 | CCC |
| Tripleitriumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2 | CCC |
+12 more in the Marinesco-Sjogren Syndrome cohort
Other indications for rp3
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CCC · 53 |
| Cancer | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. rp3 in Marinesco-Sjogren Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rp3-marinesco-sjogren-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →